{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:32:41Z","timestamp":1790231561874,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014849","name":"Bayer Science & Education Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014849","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MOST - DKFZ"},{"name":"ISF collaboration with Canada"},{"name":"the personalised medicine ISF grant"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB841"],"award-info":[{"award-number":["SFB841"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ERC advance - GA","award":["No. 786575 \u2013 RxmiRcanceR"],"award-info":[{"award-number":["No. 786575 \u2013 RxmiRcanceR"]}]},{"DOI":"10.13039\/501100003977","name":"Israeli Science Foundation","doi-asserted-by":"crossref","award":["904\/2020"],"award-info":[{"award-number":["904\/2020"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Prognostic biomarkers identifying patients with early tumor progression after local ablative therapy remain an unmet clinical need. The aim of this study was to investigate circulating miR-21 and miR-210 levels as prognostic biomarkers of HCC treated by CT-guided high-dose rate brachytherapy (HDR-BT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>24 consecutive HCC patients (BCLC A and B) treated with CT-guided HDR-BT (1\u2009\u00d7\u200915\u00a0Gy) were included in this prospective IRB-approved study. RT-PCR was performed to quantify miR-21 and miR-210 levels in blood samples acquired prior to and 2 d after HDR-BT. Follow-up imaging (contrast-enhanced liver MRI and whole-body CT) was performed in 3\u00a0months follow-up intervals. Therapy response was assessed with patients classified as either responders or non-responders (12 each). Responders were defined as having no local or diffuse systemic progression within 6\u00a0months and no diffuse systemic progression exceeding 3 nodules\/nodule diameter\u2009&gt;\u20093\u00a0cm from 6\u00a0months to 2\u00a0years. Non-responders had recurrence within 6\u00a0months and\/or tumor progression with\u2009&gt;\u20093 nodules or individual lesion diameter\u2009&gt;\u20093\u00a0cm or extrahepatic disease within two years, respectively. Biostatistics included parametric and non-parametric testing (Mann\u2013Whitney-U-test), as well as Kaplan\u2013Meier curve construction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The responder group demonstrated significantly decreasing miR-21 values 2 d post therapy compared to non-responders (median miR-21 2<jats:sup>\u2212\u0394\u0394C\u0442<\/jats:sup>: responders 0.73 [IQR 0.34], non-responders 1.53 [IQR 1.48];<jats:italic>p<\/jats:italic>\u2009=\u20090.0102). miR-210 did not show any significant difference between responders and non-responders (median miR-210 2<jats:sup>\u2212\u0394\u0394C\u0442<\/jats:sup>: responders 0.74 [IQR 0.45], non-responders 0.99 [IQR 1.13];<jats:italic>p<\/jats:italic>\u2009=\u20090.8399). Kaplan\u2013Meier curves demonstrated significantly shorter time to systemic progression for increased miR-21 (<jats:italic>p<\/jats:italic>\u2009=\u20090.0095) but not miR-210 (<jats:italic>p<\/jats:italic>\u2009=\u20090.7412), with events accumulating\u2009&gt;\u20091\u00a0year post therapy in non-responders (median time to systemic progression 397\u00a0days).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Increasing circulating miR-21 levels are associated with poor response and shorter time to systemic progression in HDR-BT-treated HCC. This proof-of-concept study provides a basis for further investigation of miR-21 as a prognostic biomarker and potential stratifier in future clinical trials of interventional oncology therapies.<\/jats:p><jats:p><jats:italic>Trial registration:<\/jats:italic>In this monocentric clinical study, we analyzed prospectively acquired data of 24 patients from the \u201cESTIMATE\u201d patient cohort (Studiennummer: DRKS00010587, Deutsches Register Klinischer Studien). Ethical approval was provided by the ethics committee \u201cEthikkommission bei der LMU M\u00fcnchen\u201d (reference number \u201c17-346\u201d) on June 20, 2017 and August 26, 2020.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13014-023-02316-2","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T04:01:41Z","timestamp":1690516901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"drks00010587","registry":"10.18810\/drks"}],"author":[{"given":"Matthias","family":"Stechele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Hirner-Eppeneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Alunni-Fabbroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Wildgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Salvermoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Schinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Ben Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"R\u00f6ssler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eithan","family":"Galun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraga Nahum","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Maximilian","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"issue":"5","key":"2316_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/annonc\/mdy510","volume":"30","author":"A Vogel","year":"2019","unstructured":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871\u20133.","journal-title":"Ann Oncol"},{"issue":"1","key":"2316_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.07.1700","volume":"78","author":"K Mohnike","year":"2010","unstructured":"Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys. 2010;78(1):172\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2316_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00066-014-0781-3","volume":"191","author":"F Collettini","year":"2015","unstructured":"Collettini F, Schreiber N, Schnapauff D, Denecke T, Wust P, Schott E, et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol. 2015;191(5):405\u201312.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"2316_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","volume":"20","author":"LFR Gebert","year":"2019","unstructured":"Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2316_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmed.2020.00007","volume":"7","author":"T Zhang","year":"2020","unstructured":"Zhang T, Yang Z, Kusumanchi P, Han S, Liangpunsakul S. Critical role of microRNA-21 in the pathogenesis of liver diseases. Front Med (Lausanne). 2020;7:7.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"2316_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/gutjnl-2015-311314","volume":"65","author":"D Blaya","year":"2016","unstructured":"Blaya D, Coll M, Rodrigo-Torres D, Vila-Casadesus M, Altamirano J, Llopis M, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut. 2016;65(9):1535\u201345.","journal-title":"Gut"},{"issue":"3","key":"2316_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/jcm5030038","volume":"5","author":"M Kitano","year":"2016","unstructured":"Kitano M, Bloomston PM. Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis. J Clin Med. 2016;5(3):38.","journal-title":"J Clin Med"},{"issue":"10","key":"2316_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/bmm-2018-0096","volume":"12","author":"JS Yoon","year":"2018","unstructured":"Yoon JS, Kim G, Lee YR, Park SY, Tak WY, Kweon YO, et al. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark Med. 2018;12(10):1105\u201314.","journal-title":"Biomark Med"},{"issue":"6","key":"2316_CR9","first-page":"7234","volume":"8","author":"CS Huang","year":"2015","unstructured":"Huang CS, Yu W, Cui H, Wang YJ, Zhang L, Han F, et al. Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8(6):7234\u20138.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"2316_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","volume":"133","author":"F Meng","year":"2007","unstructured":"Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647\u201358.","journal-title":"Gastroenterology"},{"issue":"1","key":"2316_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13046-018-0965-2","volume":"37","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37(1):324.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2316_CR12","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/hep.24614","volume":"54","author":"Q Ying","year":"2011","unstructured":"Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011;54(6):2064\u201375.","journal-title":"Hepatology"},{"issue":"5","key":"2316_CR13","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.3892\/or.2016.5129","volume":"36","author":"Y Yang","year":"2016","unstructured":"Yang Y, Zhang J, Xia T, Li G, Tian T, Wang M, et al. MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. Oncol Rep. 2016;36(5):2553\u201362.","journal-title":"Oncol Rep"},{"issue":"3","key":"2316_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jvir.2020.10.024","volume":"32","author":"T Andrasina","year":"2021","unstructured":"Andrasina T, Juracek J, Zavadil J, Cechova B, Rohan T, Vesela P, et al. Thermal ablation and transarterial chemoembolization are characterized by changing dynamics of circulating MicroRNAs. J Vasc Interv Radiol. 2021;32(3):403\u201311.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"2316_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"4","key":"2316_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"11","key":"2316_CR17","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4254\/wjh.v12.i11.1031","volume":"12","author":"M Franck","year":"2020","unstructured":"Franck M, Thon C, Schutte K, Malfertheiner P, Link A. Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World J Hepatol. 2020;12(11):1031\u201345.","journal-title":"World J Hepatol"},{"key":"2316_CR18","doi-asserted-by":"publisher","first-page":"8848158","DOI":"10.1155\/2020\/8848158","volume":"2020","author":"X Huang","year":"2020","unstructured":"Huang X, Xiong Y, Yang J, Yang G, Li J. The prognostic significance of miR-21 expression among surgically resected hepatocellular carcinoma patients: evidence from a meta-analysis and retrospective cohort study. Biomed Res Int. 2020;2020:8848158.","journal-title":"Biomed Res Int"},{"issue":"8","key":"2316_CR19","first-page":"4169","volume":"11","author":"C Zhu","year":"2018","unstructured":"Zhu C, Zhang M, Hu J, Li H, Liu S, Li T, et al. Prognostic effect of IL-6\/JAK2\/STAT3 signal-induced microRNA-21-5p expression on short term recurrence of hepatocellular carcinoma after hepatectomy. Int J Clin Exp Pathol. 2018;11(8):4169\u201378.","journal-title":"Int J Clin Exp Pathol"},{"issue":"27","key":"2316_CR20","doi-asserted-by":"publisher","first-page":"44050","DOI":"10.18632\/oncotarget.17211","volume":"8","author":"X Guo","year":"2017","unstructured":"Guo X, Lv X, Lv X, Ma Y, Chen L, Chen Y. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. 2017;8(27):44050\u20138.","journal-title":"Oncotarget"},{"issue":"3","key":"2316_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrc3672","volume":"14","author":"KF Chu","year":"2014","unstructured":"Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199\u2013208.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2316_CR22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.21873\/invivo.12955","volume":"36","author":"R Damm","year":"2022","unstructured":"Damm R, Pech M, Haag F, Cavalli P, Gylstorff S, Omari J, et al. TNF-alpha indicates radiation-induced liver injury after interstitial high dose-rate brachytherapy. In Vivo. 2022;36(5):2265\u201374.","journal-title":"In Vivo"},{"issue":"10","key":"2316_CR23","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s00432-022-04041-x","volume":"148","author":"R Damm","year":"2022","unstructured":"Damm R, Pech M, Cavalli P, Haag F, Gylstorff S, Omari J, et al. Correlation of chemokines and growth factors with radiation-induced liver injury after interstitial high dose rate (HDR) brachytherapy of liver metastases. J Cancer Res Clin Oncol. 2022;148(10):2815\u201326.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"2316_CR24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.31557\/APJCP.2019.20.5.1587","volume":"20","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen Z, Feng L, Jiang P, Li X, Wang X. Ionizing radiation-inducible microRNA-21 induces angiogenesis by directly targeting PTEN. Asian Pac J Cancer Prev. 2019;20(5):1587\u201393.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2316_CR25","doi-asserted-by":"crossref","first-page":"2892917","DOI":"10.1155\/2020\/2892917","volume":"2020","author":"J Li","year":"2020","unstructured":"Li J, Wei H, Liu Y, Li Q, Guo H, Guo Y, et al. Curcumin inhibits hepatocellular carcinoma via regulating miR-21\/TIMP3 Axis. Evid Based Complement Alternat Med. 2020;2020:2892917.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2316_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12935-020-01394-6","volume":"20","author":"SH Javanmard","year":"2020","unstructured":"Javanmard SH, Vaseghi G, Ghasemi A, Rafiee L, Ferns GA, Esfahani HN, et al. Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies. Cancer Cell Int. 2020;20:384.","journal-title":"Cancer Cell Int"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02316-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02316-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02316-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T05:45:52Z","timestamp":1729835152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02316-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02316-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"18 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this monocentric clinical study, we analyzed prospectively acquired data of 24 patients from the \u201cESTIMATE\u201d patient cohort (Studiennummer: DRKS00010587, Deutsches Register Klinischer Studien). Ethical approval was provided by the ethics committee \u201cEthikkommission bei der LMU M\u00fcnchen\u201d (reference number \u201c17-346\u201d) on June 20, 2017 and August 26, 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients provided written informed consent for both the local ablative treatment and study inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The work of Eithan Galun was supported by grants from\u00a0MOST - DKFZ, the ISF collaboration with Canada,\u00a0the personal ISF, the\u00a0personalised\u00a0medicine\u00a0ISF grant, the Deutsche\u00a0Forschungsgemeinschaft, Bonn, Germany (SFB841) and the ERC advance - GA No. 786575 \u2013 RxmiRcanceR. The work of Shraga Nahum Goldberg was supported by Grant 904\/2020 from Israeli Science Foundation. The work of Henrike Link was supported by funding from the Bayer Science & Education Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}